Bioinspired detoxification of blood: The efficient removal of anthrax toxin protective antigen using an extracorporeal macroporous adsorbent device

Scientific Reports
Ganesh C IngavleSusan R Sandeman

Abstract

Whilst various remedial human monoclonal antibodies have been developed to treat the potentially life-threatening systemic complications associated with anthrax infection, an optimal and universally effective administration route has yet to be established. In the later stages of infection when antibody administration by injection is more likely to fail one possible route to improve outcome is via the use of an antibody-bound, adsorbent haemoperfusion device. We report here the development of an adsorbent macroporous polymer column containing immobilised B. anthracis exotoxin-specific antibodies, PANG (a non-glycosylated, version of a plant-produced human monoclonal antibody) and Valortim (a fully human monoclonal N-linked glycosylated antibody), for removal of anthrax protective antigen (PA) from freshly frozen human plasma and human whole blood. In addition, we have demonstrated that continuous extracorporeal blood recirculation through a Valortim-bound haemoperfusion column significantly reduced the blood plasma concentration of anthrax PA over 2 hours using an in vivo PA rat infusion model. This work provides proof-of-concept evidence to support the development of such alternative detoxification platforms.

References

Jan 1, 1978·Journal of Immunological Methods·D M Gersten, J J Marchalonis
Mar 11, 1992·Journal of General Microbiology·J W Ezzell, T G Abshire
Jan 26, 1996·Journal of Biotechnology·A V StepanovN A Staritsin
Feb 27, 1997·Nature·C PetosaR C Liddington
Jan 1, 1997·Biosensors & Bioelectronics·G P AndersonK D King
Mar 6, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·J Turková
Sep 9, 1999·The New England Journal of Medicine·T C DixonP C Hanna
Mar 29, 2001·Journal of Chromatography. B, Biomedical Sciences and Applications·D JosicA Jungbauer
Nov 9, 2001·Nature·K A BradleyJ A Young
Dec 19, 2001·Emerging Infectious Diseases·J A JerniganUNKNOWN Anthrax Bioterrorism Investigation Team
May 1, 2002·JAMA : the Journal of the American Medical Association·Thomas V InglesbyUNKNOWN Working Group on Civilian Biodefense
Jun 4, 2002·Nature Biotechnology·Jennifer A MaynardGeorge Georgiou
Jun 13, 2002·Journal of Chromatography. a·Hanfa ZouQuanzhou Luo
Sep 11, 2003·Biotechnology and Bioengineering·R DanczykA Rundell
Sep 17, 2004·Nature Reviews. Microbiology·G Jonah A Rainey, John A T Young
Aug 1, 2006·The American Journal of Pathology·Deborah J Stearns-KurosawaShinichiro Kurosawa
Jan 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John D Grabenstein
Jul 10, 2009·The New England Journal of Medicine·Thi-Sau MigoneSally D Bolmer
Dec 17, 2011·Toxins·Jeffrey W FroudeThibaut Pelat
Dec 12, 2012·Advances in Colloid and Interface Science·Vladimir M Gun'koSergey V Mikhalovsky
Jan 23, 2014·Emerging Infectious Diseases·Katherine A HendricksUNKNOWN Workgroup on Anthrax Clinical Guidelines
Dec 10, 2014·Antimicrobial Agents and Chemotherapy·Thi-Sau MigoneGabriel Meister
Dec 4, 2015·MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports·William A BowerUNKNOWN Centers for Disease Control and Prevention (CDC)
Mar 28, 2017·Critical Care : the Official Journal of the Critical Care Forum·Klaus KogelmannMatthias Drüner

❮ Previous
Next ❯

Citations

Sep 2, 2020·Journal of Biomaterials Science. Polymer Edition·Ayana NakanoKoichi Kato
Jul 31, 2020·Expert Opinion on Biological Therapy·Manish ManishRakesh Bhatnagar

❮ Previous
Next ❯

Methods Mentioned

BETA
scanning electron microscopy
glycosylation
enzyme-linked immunosorbent assay
ELISA

Software Mentioned

GraphPad
Quantachrome
PoreWin
Quantachrome ASiQwin
GraphPad Prism

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.